Previous 10 | Next 10 |
TUCSON, Ariz., March 22, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the year ...
Gainers: DiDi Global (DIDI) +54%. Zhihu (ZH) +47%. Lizhi (LIZI) +46%. Kidpik (PIK) +42%. StoneCo (STNE) +41%. Tuya (TUYA) +39%. 111 (YI) +37%. Aesthetic Medical International Holdings (AIH) +36%. Cuentas (CUEN) +38%. Redbox Entertainment (RDBX) +36%. Losers: Ambac Financial Group (AMBC) -22%....
Gainers: BioVie (BIVI) +16%. Progenity (PROG) +16%. Kezar Life Sciences (KZR) +14%. Codiak BioSciences (CDAK) +13%. Ensysce Biosciences (ENSC) +10%. Losers: Nymox Pharmaceutical (NYMX) -29%. HTG Molecular Diagnostics (HTGM) -14%. Zhongchao (ZC...
HTG Molecular Diagnostics (NASDAQ:HTGM) has slipped -7.08% pre-market on announcing a $7.5M private placement. The life science company entered into a definitive securities purchase agreement with a leading healthcare investor to sell 3,244,987 units at a price of $2.312/unit to the...
TUCSON, Ariz., March 18, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a definitive securities purchase agreement to sell securities in a pri...
TUCSON, Ariz., Feb. 03, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed Robert Spitale, Ph.D., Associate Director and...
TUCSON, Ariz., Jan. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed biopharmaceutical industry veteran Christophe...
Preliminary full year 2021 unaudited revenue of $8.9 million Cash, cash equivalents and short-term marketable securities of $21.9 million as of December 31, 2021 TUCSON, Ariz., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG),...
TUCSON, Ariz., Dec. 22, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, has now expanded the potential markets and applications for its pioneeri...
TUCSON, Ariz., Dec. 16, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that internationally renowned physician-scientist Jerald Radic...
News, Short Squeeze, Breakout and More Instantly...
HTG Molecular Diagnostics Inc. Company Name:
HTGM Stock Symbol:
NASDAQ Market:
HTG Molecular Diagnostics Inc. Website:
TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biot...
TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietar...
TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlig...